Recruiting
Phase 2

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Sponsor:

Wake Forest University Health Sciences

Code:

NCT05696782

Conditions

Nonsmall Cell Lung Cancer Stage III

Unresectable Non-Small Cell Lung Carcinoma

Nonsmall Cell Lung Cancer, Stage II

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Durvalumab

the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30)

COPD Assessment Test (CAT)

Modified Medical Research Council (mMRC) dyspnea scale

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information